Charles Schweizer

892 total citations
24 papers, 703 citations indexed

About

Charles Schweizer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Charles Schweizer has authored 24 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Charles Schweizer's work include Ovarian cancer diagnosis and treatment (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Cancer Research and Treatments (4 papers). Charles Schweizer is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Cancer Research and Treatments (4 papers). Charles Schweizer collaborates with scholars based in United States, Germany and United Kingdom. Charles Schweizer's co-authors include Susan C. Weil, Martin D. Phillips, Raffit Hassan, Ira Pastan, Steven J. Cohen, Daniel A. Laheru, Ronan J. Kelly, Elad Sharon, Wenquan Wang and Daniel J. O’Shannessy and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Charles Schweizer

21 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles Schweizer United States 13 332 208 170 157 146 24 703
E. Kutarska Poland 12 440 1.3× 96 0.5× 285 1.7× 211 1.3× 274 1.9× 17 939
Mildred Felder United States 17 421 1.3× 86 0.4× 145 0.9× 467 3.0× 445 3.0× 39 1.1k
Lindsey Rolfe United States 12 622 1.9× 199 1.0× 179 1.1× 78 0.5× 374 2.6× 30 856
Sterre T. Paijens Netherlands 7 440 1.3× 145 0.7× 65 0.4× 319 2.0× 168 1.2× 12 709
Françoise Drusch France 14 544 1.6× 195 0.9× 92 0.5× 137 0.9× 215 1.5× 17 924
Chia‐Yen Huang Taiwan 16 228 0.7× 68 0.3× 294 1.7× 77 0.5× 232 1.6× 38 757
Thaïs Baert Belgium 16 400 1.2× 86 0.4× 558 3.3× 260 1.7× 149 1.0× 47 955
C Sakakura Japan 17 267 0.8× 308 1.5× 83 0.5× 57 0.4× 354 2.4× 28 983
Margaret E. Gatti‐Mays United States 16 746 2.2× 170 0.8× 41 0.2× 539 3.4× 306 2.1× 74 1.1k
Darryl A. Oble United States 12 733 2.2× 133 0.6× 42 0.2× 656 4.2× 153 1.0× 15 1.1k

Countries citing papers authored by Charles Schweizer

Since Specialization
Citations

This map shows the geographic impact of Charles Schweizer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Schweizer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Schweizer more than expected).

Fields of papers citing papers by Charles Schweizer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Schweizer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Schweizer. The network helps show where Charles Schweizer may publish in the future.

Co-authorship network of co-authors of Charles Schweizer

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Schweizer. A scholar is included among the top collaborators of Charles Schweizer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Schweizer. Charles Schweizer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hoffe, Sarah E., Jessica M. Frakes, Todd A. Aguilera, et al.. (2020). Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). International Journal of Radiation Oncology*Biology*Physics. 108(5). 1399–1400. 12 indexed citations
2.
Nicolaides, Nicholas C., Charles Schweizer, Elizabeth B. Somers, et al.. (2018). CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients. Cancer Biology & Therapy. 19(7). 622–630. 11 indexed citations
3.
D’Angelo, Sandra P., Omid Hamid, Ahmad A. Tarhini, et al.. (2017). A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. Investigational New Drugs. 36(1). 103–113. 21 indexed citations
4.
Wang, Wenquan, Elizabeth B. Somers, J. Bradford Kline, et al.. (2017). FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125. Cytogenetic and Genome Research. 152(4). 169–179. 16 indexed citations
5.
O’Shannessy, Daniel J., Charles Schweizer, Wenquan Wang, et al.. (2017). Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer. Genomics. 109(3-4). 251–257. 15 indexed citations
6.
7.
O’Shannessy, Daniel J., Charles Schweizer, Wenquan Wang, et al.. (2016). Analysis of molecular and protein signatures on farletuzumab pharmacokinetics from a phase 3 ovarian cancer study.. Journal of Clinical Oncology. 34(15_suppl). e14508–e14508. 1 indexed citations
8.
9.
Kim, Kenneth H., Danijela Jelovac, Deborah K. Armstrong, et al.. (2015). Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer. Gynecologic Oncology. 140(2). 210–214. 29 indexed citations
10.
Chawla, Sant P., Patrick Schöffski, Jean‐Yves Blay, et al.. (2015). A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.. Journal of Clinical Oncology. 33(15_suppl). TPS10577–TPS10577. 1 indexed citations
11.
Farrell, Colm, Charles Schweizer, Susan C. Weil, et al.. (2012). Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer. Cancer Chemotherapy and Pharmacology. 70(5). 727–734. 15 indexed citations
12.
Hassan, Raffit, Thierry Jahan, Hedy L. Kindler, et al.. (2012). Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial.. Journal of Clinical Oncology. 30(15_suppl). 7030–7030. 9 indexed citations
13.
14.
Coleman, Robert L., Annette Bicher, Donald Richards, et al.. (2010). Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.. Journal of Clinical Oncology. 28(15_suppl). 5001–5001. 20 indexed citations
15.
Konner, Jason, Katherine M. Bell‐McGuinn, Paul Sabbatini, et al.. (2010). Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study. Clinical Cancer Research. 16(21). 5288–5295. 133 indexed citations
16.
Hassan, Raffit, Charles Schweizer, Barbara Schüler, et al.. (2009). Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer. 68(3). 455–459. 61 indexed citations
17.
Collins‐Thompson, Kevyn, Charles Schweizer, & Susan Dumais. (2001). Improved string matching under noisy channel conditions.
18.
Schweizer, Charles, et al.. (1991). Die Wirkung von herbiziden auf das sporulierungsvermögen des blattlauspathogenen PilzesErynia neoaphidis. Journal of Pest Science. 64(7). 134–136. 2 indexed citations
19.
Klotz, Ulrich & Charles Schweizer. (1980). Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels.. PubMed. 18(10). 461–5. 15 indexed citations
20.
Kern, William H. & Charles Schweizer. (1977). Sputum cytology of metastatic carcinoma of the lung.. PubMed. 20(6). 514–20. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Kutarska Breakdown of academic impact, for papers by Mildred Felder Breakdown of academic impact, for papers by Lindsey Rolfe Breakdown of academic impact, for papers by Sterre T. Paijens Breakdown of academic impact, for papers by Françoise Drusch Breakdown of academic impact, for papers by Chia‐Yen Huang Breakdown of academic impact, for papers by Thaïs Baert Breakdown of academic impact, for papers by C Sakakura Breakdown of academic impact, for papers by Margaret E. Gatti‐Mays Breakdown of academic impact, for papers by Darryl A. Oble
Rankless by CCL
2026